Every letter we have printed

I would add one omission to your list. Nobody states the headspace gas. Nitrogen-backfilled vials and air-sealed vials behave differently for any oxidation-prone sequence, and it is a single word on a certificate.

A methodological complaint. Asking somebody for their reason implies there was one. Several of the most honest accounts I have read describe a drift rather than a decision, and a questionnaire with a list of reasons will never capture that.

An observation about self-selection in the accounts you print. People who write to a publication about stopping are people who thought about it enough to write. The quiet majority who simply stopped ordering are not represented and probably outnumber the correspondents considerably.

There is a selection effect in every maintenance dataset. The people still in the study at month thirty are the people for whom it worked, and any statement about maintenance derived from them describes that subgroup rather than the original population.

Sample sizes in the withdrawal arms are typically a fraction of the initiation cohorts, which widens every interval in the interesting part of the study. Coverage tends to quote the point estimate from the smallest arm in the paper.

Reasons recorded at the point of sale would be a different dataset entirely and one nobody has ever assembled. A supplier knows precisely who stopped ordering and when, and has no reason at all to publish it.

Timing matters as much as reason. Stopping in week three and stopping in year three are different events with different consequences, and reporting a single discontinuation rate for a study collapses that entirely.

A last point about this publication’s own framing. Research-use material is not approved for human use in any jurisdiction, and a maintenance discussion conducted around such material is a discussion about a supply chain rather than about a therapy. Keeping that distinction visible is the useful thing you do.

A design point rarely made: the withdrawal arm is the only place in this literature where anybody observes what happens after stopping under controlled conditions. However narrow the question, it is the only evidence of its kind and it deserves more careful reading than it gets.

Adherence to an activity component is measured badly in almost every study, usually by self-report, and the resulting variable is not comparable between trials even where both report it.

A short note on reporting. Where a study reports training volume, it should report it in a form somebody could reproduce: sessions, exercises, sets and progression. Most report a duration in weeks and nothing else.

A ratio derived from a substudy of eighty people is being applied to a population of millions in general discussion, and the arithmetic is presented with a confidence the original authors were careful to avoid. The paper is fine; the citation chain is where the damage happens.

The body-composition substudies were substudies, and the number of participants scanned is a small fraction of the trial. That does not invalidate them and it does mean the confidence intervals are wide, which is worth printing beside the point estimates that circulate.

The soft-tissue artefact point in your bone section is underplayed. In a patient losing twenty per cent of body mass the change in overlying tissue is well outside the range the calibration was validated over, and the published analyses do not report a sensitivity analysis for it. That is not a caveat, it is a gap.

Cost is the leading reason people stop and it is discussed least, because it is not a clinical variable and therefore does not appear in clinical writing. Your treating it as a primary reason rather than a footnote is the right decision.

The distinction between stopping and pausing is made by the person and not by the data. Somebody who intends to resume is recorded as a discontinuation, and the two populations behave very differently afterwards.

Every discussion of maintenance I read assumes the person has settled on one arrangement. In practice people change source, change schedule and change what they measure, often several times, and a phase described as steady is frequently nothing of the sort.

Where an interruption was caused by supply rather than by choice, the person has no control over its length, which makes any schedule-based advice difficult to apply. That is a feature of this market that the clinical literature has no reason to address.

Retitration after an interruption is discussed as though the tolerance acquired during the first course persists. Whether it does is an empirical question and I can find no study addressing it in this class.

The energetics of a smaller body are sufficient on their own to produce a decelerating curve, and that explanation is rarely offered alongside the pharmacological ones. It is the null hypothesis and it is not being tested against.

Fluid shifts are large enough to mask several weeks of underlying change on a scale, which means a short plateau in self-measured data may be nothing at all. Anybody reading their own weekly numbers is reading a signal with a comparable amount of noise on it.

The most important sentence in this series is that a purity certificate is silent on microbiology. Chromatography reports on molecules and says nothing whatever about organisms or their fragments, and a great many buyers read a high purity figure as a general assurance of cleanliness. The document does not make that claim and cannot.

The silence is not a conspiracy. It is what happens when nobody has an obligation, nobody has a question and the instrument that would answer it sits in a different laboratory from the one everybody already uses.

Water is the usual source and glassware is the usual carrier. Depyrogenation of the container by dry heat is the step that gets skipped in small operations, because it looks like a detail and it is the difference between a clean result and a puzzling one.

Your table of responses records four declines citing research-use-only status, and you call that a legally sound answer. It is also the answer that ends the conversation. What would you have a supplier say instead?

Fracture is the endpoint that matters and no study in this area is remotely powered for it. Everything published is a surrogate, and the relationship between the surrogate and the outcome is itself an active research question.

Areal density is confounded by body size, which is precisely what is changing. That is a real limitation of the standard measurement in exactly this population, and the volumetric alternatives are not widely available.

Hydrolysis at the peptide bond is slow at refrigerated temperatures and not at room temperature, and the difference across that range is much larger than people assume from the small numerical gap.

Oxidation of methionine is the other route worth naming and it is driven by headspace oxygen and by trace metals. A vial filled under nitrogen is materially better protected, and whether the fill was under nitrogen is not something any certificate I hold discloses.

Residual moisture and cake structure are set by the freeze-drying cycle, which is a manufacturing parameter nobody in this market ever asks about. It determines the stability of everything downstream of it.

Excipients determine solution behaviour substantially and are not disclosed on most certificates. Two vials of the same molecule with different buffer systems will not behave alike, and the buyer cannot tell them apart.

A brief thank you from a reader who works well outside this field and follows it anyway. The writing assumes intelligence without assuming background, which is harder than it looks.

Glycated haemoglobin reflects roughly the preceding two to three months, weighted towards the more recent weeks, which means a value taken four weeks after a change is a poor test of that change. It is the commonest misreading of the analyte and it is entirely avoidable by waiting.

Insulin and C-peptide are frequently ordered without a clear question in mind, which is the general failing your panel-design section describes. Ordered to answer something specific they are informative; ordered to complete a picture they generate findings that require chasing.

Timing consistency is undervalued. Same laboratory, same time of day, same fasting state removes a large part of the noise between draws for no cost whatever, and it makes a modest true change visible that would otherwise be buried.

The activity component in these protocols is described in a sentence and would take a page to reproduce. Without the page, no reader can tell whether their own practice resembles what was studied.

Strength can be maintained while cross-sectional area falls, because a good deal of early strength change is neural. Readers using performance as a proxy for tissue are using a proxy that moves for other reasons, in both directions.

An accreditation body will investigate a complaint about a laboratory within its scope. Almost nobody in this market knows that, and I would put the route in a sidebar: it is free, it is real, and it is used vanishingly rarely.

Speaking as somebody who has signed a good many of these: the signature is not a formality to the person signing it. It is the reason I have refused to release a report on a run whose suitability data I did not like, and the reason I would refuse again. The document is one of the few places in this trade where an individual is on the record.

I would add a field for what was not tested. Certificates are read as complete accounts of a material, and the reason they are not is invisible: everything absent is absent silently. A line reading "sterility and endotoxin not determined" would be more informative than half the values above it.